CANCERSPOT: AI-BASED MULTI-CANCER BLOOD TEST

20 Nov 2026

Tags: Prelims   Current events of national and international importance

Source: The Hindu

Context: Bengaluru-based Strand Life Sciences developed CancerSpot, an AI-based blood test for detecting multiple types of cancer.

  • Technology: Combines DNA sequencing and Artificial Intelligence (AI) to detect cancer-associated DNA methylation patterns.
  • Working mechanism:
    • Cells release DNA fragments into the bloodstream, called cell-free DNA (cfDNA).
    • Cancer cells release tumour-derived DNA fragments carrying distinct molecular changes.
    • The test analyses DNA methylation patterns to distinguish cancerous from normal cells.
  • DNA methylation: Chemical modification of DNA that regulates gene expression without changing the DNA sequence.
  • Performance: Detected 72% of cancer cases, with a 1.4% false-positive rate.
  • Clinical validation: Study involved 1,480 participants, 43 hospitals and 14 cancer types, conducted over four years.
  • Significance: Enables screening for multiple cancers through a single blood test, potentially reducing the need for invasive tissue biopsy during initial detection.
  • Publication: Findings published in the Proceedings of the National Academy of Sciences (PNAS), a peer-reviewed scientific journal.

Prelims Value Addition

  • Liquid biopsy: Detects cancer-related biomarkers (e.g., circulating tumour DNA) in body fluids, particularly blood, instead of obtaining tumour tissue surgically.
  • False-positive result: Test indicates cancer in a person who does not actually have cancer; may lead to unnecessary investigations.

Prelims Question

Q1. With reference to DNA methylation and cancer detection, consider the following statements:

  1. DNA methylation can regulate gene expression without altering the underlying DNA sequence.
  2. Cell-free DNA (cfDNA) is found exclusively in the bloodstream of cancer patients.
  3. Liquid biopsy can detect cancer-associated biomarkers in body fluids without requiring surgical removal of tumour tissue.
  4. AI-based analysis of DNA methylation patterns can help distinguish tumour-derived DNA from normal cell-free DNA.

Which of the statements given above are correct?

(a) 1 and 3 only
(b) 1, 3 and 4 only
(c) 2 and 4 only
(d) 1, 2, 3 and 4

Answer: (b) 

Explanation:

  • Statement 1 is Correct: DNA methylation is an epigenetic modification that influences gene expression without changing the DNA sequence.
  • Statement 2 is Incorrect: cfDNA is also released by normal cells and is present in healthy individuals.
  • Statement 3 is Correct: Liquid biopsy analyses biomarkers in blood and other body fluids rather than requiring tissue extraction.
  • Statement 4 is Correct: Cancer cells may release DNA carrying distinct molecular patterns that can be identified through analysis.